A promising new approach to help scientists characterize the tumor microenvironment, condition immune cells to fight cancer, and manufacture cell therapies has come from an innovative cell incubation ...

Avance Biosciences opened its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and centralize the company’s capabilities in potency and functional ...

Iovance Biotherapeutics has made progress in developing potency assays for lifileucel, a tumor-infiltrating lymphocyte therapy for advanced melanoma patients. Developing potency assays for lifileucel ...

Thepatent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral ...

The primary causes of disability and mortality in the US are chronic diseases such as cancer, neurodegenerative disorders, cardiovascular disease, obesity, arthritis, and diabetes. The increase in ...

OTC deficiency is a rare genetic condition and the most prevalent urea cycle disorder. Newborns with neonatal onset OTC deficiency exhibit hyperammonemia symptoms shortly after birth, including ...

MIAMI - Longeveron Inc. (NASDAQ:LGVN) announced today that the China National Intellectual Property Administration has granted a patent covering potency assay methods for assessing human mesenchymal ...

Let’s face it: Nobody pursues a career in science for the joy of culturing cells. But this thankless and time-intensive task is the backbone of biological research. When it’s done extremely well, the ...

The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, ...

Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron Thepatent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived ...